Company news: Amgen and Eli Lilly

Share this article:

Amgen's bone drug denosumab won approval for two new indications yesterday, both under the brand name Prolia: to increase bone mass in breast cancer patients on aromatase inhibitor therapy, and for prostate cancer patients undergoing androgen-deprivation therapy. Denosumab is also sold under the brand name Xgeva for reducing fractures and other bone problems in patients with bone metastases from solid tumors. Amgen is studying the drug for other uses, as well.

Eli Lilly said using patient navigators to guide subjects through the treatment process, as well as taking into account language and ethnic considerations of potential participants, can increase minority involvement in clinical trials. In a lung cancer study that began with 19% minority representation, after the interventions were introduced, minority participation among remaining enrollees increased to 43%.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.